In 2016, a phase II study by Tarpgaard et al. found that metastatic colorectal cancer (mCRC) patients, who were refractory to treatment with oxaliplatin-based chemotherapy, had TOP2A gene amplification in their tumor cells (55). The gene discussed is TOP2A; the disease is metastatic colorectal cancer.